Awareness of the severity of liver disease re-examined using software-combined biomarkers of liver fibrosis and necroinflammatory activity
Open Access
Abstract
Background Effective antiviral treatment (direct-acting antiviral agents (DAAs)), the requirement for a fibrosis score to support DDA reimbursement and a screening strategy, such as the USA baby boomer campaign, should lead to an increased awareness of liver disease severity. Objective To compare the awareness of liver disease severity between the USA and France, two countries with similar access to hepatitis C virus (HCV) and hepatitis B virus (HBV) treatments, similar rules for treatment reimbursement and similar availability of validated fibrosis tests, but with different policies, as France has no screening. Method The global database of the FibroTest–ActiTest, including 1 085 657 subjects between 2002 and 2014, was retrospectively analysed. Awareness was defined as the test prescription rate and was compared between the USA and France, according to year of birth, gender and dates of DAA availability and screening campaign (2013–2014). Results In the USA 252 688 subjects were investigated for HCV, with a dramatic increase (138%) in the test rate in 2013–2014 (119 271) compared with 2011–2012 (50 031). In France 470 762 subjects were investigated (subjects with HCV and other disease) and the rates were stable. In USA 82.4% of subjects and in France 84.6% were classified as either the highest or lowest priority. The most striking difference was the higher test rate in women born between 1935 and 1944 in France 30 384/200 672 (15.1%) compared with the USA 8035/97 079 (8.3%) (OR=1.98 (95% CI 1.93 to 2.03) pConclusions This study highlighted in the USA the association between awareness of liver disease and both the HCV campaign and DAA availability. In comparison with France, there was a dramatically lower awareness of cirrhosis in the USA for women born between 1935 and 1944.Keywords
This publication has 52 references indexed in Scilit:
- EASL Clinical Practice Guidelines: Management of hepatitis C virus infectionJournal of Hepatology, 2014
- The new paradigm of hepatitis C therapy: integration of oral therapies into best practicesJournal of Viral Hepatitis, 2013
- The State of US Health, 1990-2010JAMA, 2013
- Blood Tests to Diagnose Fibrosis or Cirrhosis in Patients With Chronic Hepatitis C Virus InfectionAnnals of Internal Medicine, 2013
- Cost Effectiveness of Fibrosis Assessment Prior to Treatment for Chronic Hepatitis C PatientsPLOS ONE, 2011
- PNPLA3 polymorphism influences liver fibrosis in unselected patients with type 2 diabetesLiver International, 2011
- Applicability and precautions of use of liver injury biomarker FibroTest. A reappraisal at 7 years of ageBMC Gastroenterology, 2011
- First-line assessment of patients with chronic liver disease with non-invasive techniques and without recourse to liver biopsyJournal of Hepatology, 2011
- ActiTest accuracy for the assessment of histological activity grades in patients with chronic hepatitis C, an overview using Obuchowski measureGastroentérologie Clinique Et Biologique, 2010
- Biomarkers of Liver Injury for Hepatitis Clinical Trials: A Meta-Analysis of Longitudinal StudiesAntiviral Therapy, 2010